NASDAQ · EW
Healthcare · Medical - Devices
$91.60
Down-$0.96 (-1.04%)
Updated Aug 15, 2026, 7:50 AM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
EW closed at $91.60 after 21 trading sessions, up 6.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $92.92 | $92.92 | $91.48 | $91.60 | 2.85M |
| Aug 13, 2026 | $93.48 | $93.75 | $92.21 | $92.56 | 2.81M |
| Aug 12, 2026 | $91.66 | $93.379 | $91.66 | $93.05 | 2.34M |
| Aug 11, 2026 | $92.03 | $93.91 | $91.975 | $93.66 | 3.14M |
| Aug 10, 2026 | $89.38 | $92.81 | $88.605 | $92.03 | 4.44M |
| Aug 7, 2026 | $89.44 | $90.36 | $88.77 | $89.72 | 2.44M |
| Aug 6, 2026 | $88.98 | $89.36 | $87.945 | $89.32 | 2.66M |
| Aug 5, 2026 | $89.70 | $91.02 | $88.54 | $88.97 | 3.67M |
| Aug 4, 2026 | $88.50 | $89.83 | $88.16 | $89.60 | 4.32M |
| Aug 3, 2026 | $86.89 | $88.905 | $86.39 | $88.82 | 3.96M |
| Jul 31, 2026 | $87.08 | $87.08 | $85.24 | $86.07 | 3.95M |
| Jul 30, 2026 | $85.41 | $87.035 | $85.05 | $86.92 | 3.94M |
| Jul 29, 2026 | $84.79 | $86.00 | $82.905 | $85.76 | 5.59M |
| Jul 28, 2026 | $84.60 | $85.51 | $83.22 | $83.68 | 5.61M |
| Jul 27, 2026 | $83.30 | $84.12 | $81.155 | $83.04 | 6.71M |
| Jul 24, 2026 | $88.00 | $89.0801 | $82.53 | $82.63 | 10.48M |
| Jul 23, 2026 | $83.52 | $84.45 | $82.99 | $83.82 | 6.91M |
| Jul 22, 2026 | $85.22 | $85.5299 | $84.02 | $84.37 | 4.51M |
| Jul 21, 2026 | $83.99 | $84.87 | $83.17 | $84.55 | 5.57M |
| Jul 20, 2026 | $85.97 | $86.275 | $84.87 | $85.00 | 3.75M |
| Jul 17, 2026 | $86.96 | $87.06 | $85.30 | $85.73 | 5.23M |
The latest Smart Investors Daily articles mentioning EW.
EW research
Company profile and research snapshot.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 24, 2026 | Leerink Partners | Outperform | — |
| Jul 24, 2026 | Piper Sandler | Overweight | — |
| Jul 24, 2026 | JP Morgan | Overweight | — |
| Jul 16, 2026 | Truist Securities | Hold | — |
| Jul 15, 2026 | Mizuho | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 4, 2026
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Yahoo · Jul 30, 2026
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Yahoo · Jul 29, 2026
Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.
Yahoo · Jul 28, 2026
DUBLIN, July 28, 2026--CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare exe
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EW.
